Press Releases

Oxford Gene Technology (OGT), a Sysmex Group Company, has today announced the expansion of its SureSeq™ range of next generation sequencing (NGS) panels to facilitate the interrogation of genes involved in breast and ovarian cancer, and myeloid disorders. The two new panels include a comprehensive 70-gene myeloid panel and a 7-gene breast and ovarian cancer panel that incorporates copy number variation (CNV) detection. Both have been designed based on the most recent literature and with

Novus Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, announced that the first subject has been enrolled in the Phase 2a clinical trial evaluating AT-1501, the Company’s lead product candidate, in adults with amyotrophic lateral sclerosis (ALS). AT-1501 blocks the activation of the CD40L pathway, which has

TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, and Augmenta Bioworks, Inc., a biotechnology company enabling breakthroughs in medicine through immune profiling, jointly announce that both companies have entered into a worldwide Joint Development and Collaboration Agreement to develop novel commercial products incorporating Augmenta’s human-derived monoclonal antibodies (mAbs) for potential COVID-19 therapeutics. Under the terms of the Agreement, both co

Mylan N.V. and Pfizer Inc. announced that the U.S. Federal Trade Commission (the “FTC”) accepted a proposed consent order, which concludes the FTC’s review of the proposed combination of Mylan and Pfizer’s Upjohn Business. The parties have now obtained all required antitrust clearances for the proposed transaction. The combination will be effected through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. will be spun off to Pfizer’s stoc

OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, announced  that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to evaluate the efficacy of OLX10010 as an adjunct therapy to reduce the recurrence of hypertrophic scars after scar revision surgery. “We are pleased to receive FDA clearance to advance investigation of OLX10010 and look forward to working with investigators to begin en

Agilex Biolabs, Australia's most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, congratulates client company Shasqi on the announcement of the first-ever application of click chemistry in humans, with the launch of the Company's lead clinical candidate, SQ3370. Shasqi is the first Y Combinator-backed biotech company to reach clinical development. San Francisco-based Shasqi said in the announcement: First Patients Dosed in Phase 1 Cl

Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN™¥. “Nexus Pharmaceuticals is very pleased to announce the approval of Succinylcholine Chloride. This critical need drug has seen an increased demand due to the COVID-19 pandemic and Nexus will be ready to meet the challenge. This approval further cements Ne

Lantheus Holdings, Inc., parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, announced a strategic collaboration with Insightec Ltd., a global healthcare company focused on the therapeutic power of acoustic energy. Under the agreement, Lantheus’ microbubbles will be used in combination with Insightec’s investigational MR-guided Focused Ultra

AgeX Therapeutics, Inc., a biotechnology company developing innovative regenerative therapeutics to treat human diseases to increase healthspan and combat the effects of aging, and ImStem Biotechnology, Inc. (“ImStem”), a biopharmaceutical company developing embryonic stem cell (ESC) derived mesenchymal stem cells (MSCs),  announced that ImStem has obtained from AgeX a non-exclusive, royalty-bearing sublicense to use AgeX’s clinical-grade ESC line ESI-053 to derive ImSt

Releviate™ Therapeutics, a bio-pharmaceutical company addressing the needs of patients suffering from chronic pain, signs an exclusive license for two patent pending human monoclonal antibodies developed by researchers at the University of California, Riverside and Duke University. Pre-clinical studies suggest the RLVT-9-01 (anti-MMP-9 antibody) and the RLVT-14-02 (anti-MMP-14 antibody) could directly target the specific matrix metalloproteinases (MMPs) activating neuropathic pain pathw